This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Introduction: New Trends in Treating Premenstrual Dysphoric Disorder

Lee S. Cohen, MD

Published: October 30, 2000

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Premenstrual dysphoric disorder (PMDD) affects 3% to 8% of women with regular menstrual cycles. Symptoms of PMDD include a range of emotional and somatic symptoms that are limited to the luteal phase of the menstrual cycle (the last 14 days prior to menses) and that interfere with occupational and social functioning. Clinicians who care for women must differentiate PMDD from a spectrum of other conditions that may present with similar symptoms.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 61

Quick Links: Psychiatry


Sign-up to stay
up-to-date today!


Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...